Value of dopachrome tautomerase detection in the assessment of melanocytic tumors

Melanoma Research

Volumn 24, Issue 3, 2014, Pages 219-236

  Filimon, Anca ^a   Zurac, Sabina A ^b   Milac, Adina L ^a   Sima, Livia E ^a   Petrescu, Stefana M ^a   Negroiu, Gabriela ^a  

^a INSTITUTE OF BIOCHEMISTRY OF THE ROMANIAN ACADEMY   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

DOPACHROME TAUTOMERASE; MONOPHENOL MONOOXYGENASE; SMALL INTERFERING RNA; DOPACHROME ISOMERASE; ISOMERASE; TUMOR MARKER;

AMELANOTIC MELANOMA; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL POPULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CUTANEOUS MELANOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INNERVATION; MELANOCYTIC NEVUS; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETORY PATHWAY; TUMOR GROWTH; WESTERN BLOTTING; COMPARATIVE STUDY; ENZYMOLOGY; EVALUATION STUDY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; MELANOCYTE; METABOLISM; PATHOLOGY; PHENOTYPE; PIGMENTED NEVUS; PREDICTIVE VALUE; PROGNOSIS; RNA INTERFERENCE; SKIN TUMOR;

FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HELA CELLS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MELANOCYTES; MELANOMA; MONOPHENOL MONOOXYGENASE; NEVUS, PIGMENTED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA INTERFERENCE; SKIN NEOPLASMS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84899954646     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000066     Document Type: Article

References (59)

1. Sáez-Ayala M, Fernández-Pérez MP, Montenegro MF, Sánchez-del-Campo L, Chazarra S, Pinẽro-Madrona A, et al. Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res 2012; 318:1146-1159.
2. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68:2745-2754.
3. Goppner D, Leverkus M. Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma? J Skin Cancer 2011; 2011:521947.
4. Miteva M, Lazova R. Spitz nevus and atypical spitzoid neoplasm. Semin Cutan Med Surg 2010; 29:165-173.
5. Gould Rothberg BE, Rimm DL. Biomarkers: the useful and the not so useful - an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010; 130:1971-1987.
6. Filimon A, Negroiu G. Dopachrometautomerase: an old protein with new functions. Rom J Biochem 2009; 299:36-52.
7. Sun Y, Song M, Stevanović S, Jankowiak C, Paschen A, Rammensee H-G, Schadendorf D. Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer 2000; 7:399-404.
8. Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, et al. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 2010; 5:e12670.
9. Pak BJ, ChuW, Lu SJ, Kerbel RS, Ben-David Y. Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase related protein 2. Cancer Metastatis Rev 2001; 20:27-32.
10. Michard Q, Commo S, Belaidi JP, Alleaume AM, Michelet JF, Daronnat E, et al. TRP-2 specifically decreases WM35 cell sensitivity to oxidative stress. Free Radic Biol Med 2008; 44:1023-1031.
11. Sendoel A, Kohler I, Fellmann C, Lowe SW, Hengartner MO. HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature 2010; 465:577-583.
12. Takeuchi H, Kuo C, Morton DL, Wang H-J, Hoon DSB. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res 2003; 63:441-448.
13. Itakura E, Huang RR,Wen DR, Paul E,Wünsch PH, Cochran AJ. RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffinembedded tissues of melanoma and nevi. Mod Pathol 2008; 21:326-333.
14. Becker B, Roesch A, Hafner C, Stolz W, Dugas M, Landthaler M, et al. Discrimination of melanocytic tumors by cDNA array hybridization of tissues prepared by laser pressure catapulting. J Invest Dermatol 2004; 122:361-368.
15. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008; 35:433-444.
16. De Wit NJ, van Muijen GN, Ruiter DJ. Immunohistochemistry in melanocytic proliferative lesions. Histopathology 2004; 44:517-541.
17. Levy F, Muehlethaler K, Salvi S, Peitrequin A-L, Lindholm CK, Cerottini J-C, et al. Ubiquitylation of a melanosomal protein by HECT-E3 ligases serves as sorting signal for lysosomal degradation. Mol Biol Cell 2005; 16: 1777-17870.
18. Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJS, Kuppner MC, et al. Tumor-derived heat shock protein 70 peptide complexes are crosspresented by human dendritic cells. J Immunol 2002; 169:5424-5432.
19. Hopp TP, Woods KR. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA 1981; 86:152-156, Available at: http://www.bioinformatics.org/JaMBW/3/1/7/.
20. Kolaskar AS, Tongaonkar PC. A semi-emipirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 1990; 276: 172-174, Available at: http://bips.u-strasbg.fr/EMBOSS/cgi-bin/emboss.pl?-action= input&-app =antigenic.
21. Pisani DF, Deschesne CA. Skeletal Muscle Hif-1a expression is dependent on muscle fiber type. J Gen Physiol 2005; 126:173-178.
22. Czaja LS, Hogekamp C, Lamm P, Maillet F, Martinez EA, Samain E, et al. Transcriptional responses toward diffusible signals from symbiotic microbes reveal MtNFP- and MtDMI3-dependent reprogramming of host gene expression by arbuscular mycorrhizal fungal lipochitooligosaccharides. Plant Physiol 2012; 159:1671-1685.
23. Negroiu G, Branza-Nichita N, Petrescu AJ, Dwek RA, Petrescu SM. Protein specific N-glycosylation of tyrosinase and tyrosinase-related protein-1 in B16 mouse melanoma cells. Biochem J 1999; 344:659-665.
24. Filimon A, Sima LE, Appelhans D, Voit B, Negroiu G. Internalization and intracellular trafficking of poly(propylene imine) glycodendrimers with maltose shell in melanoma cells. Curr Med Chem 2012; 19:4955-4968.
25. Trefzer U, Hofmann M, Reinke S, Guo YJ, Audring H, Spagnoli G, et al. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy. Melanoma Res 2006; 16:137-145.
26. Le Poole IC, Riker A, Quevedo ME, Stennett LS,Wang E, Marincola FM, et al. Interferon-g reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 2002; 160:521-528.
27. Jiao Z, Mollaaghababa R, Pavan WJ, Antonellis A, Green ED, Hornyak TJ. Direct interaction of Sox10 with the promoter of murine Dopachrome Tautomerase (Dct) and synergistic activation of Dct expression with Mitf. Pigment Cell Res 2004; 17:352-362.
28. Negroiu G, Dwek RA, Petrescu SM. Tyrosinase-related protein-2 and -1 are trafficked on distinct routes in B16 melanoma cells. Biochem Biophys Res Commun 2005; 328:914-921.
29. Hashimoto Y, Ito Y, Kato T, Motokava T, Katagiri T, Itoh M. Expression of profiles of melanogenesis-related genes and proteins in acquired melanocytic nevus. J Cutan Pathol 2006; 33:207-215.
30. De Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Brocker EB, Renard N. Expression of gp100, MART-1, tyrosinase, and S 100 in paraffin-embedded primary melanomas and locoregional lymph node, and visceral metastases: implication for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Group. J Pathol 2001; 193:13-20.
31. Sztramska A, Dymerska D, Chwirot BW. Skin layer specific Melan-A expression during progression of human cutaneous melanoma: implications for diagnostic application of the marker. Melanoma Res 2008; 18: 259-267.
32. Pak BJ, Li Q, Kerbel RS, Ben-David Y. TYRP2-mediated resistance to cisdiamminedichloroplatinum (II) in human melanoma cells is independent of Tyr and TRP-1 expression and melanin content. Melanoma Res 2000; 10:499-505.
33. Bastian BC, Kashani-Sabet M, Hamm H, Godfrey T, Moore DH 2nd, Brocker EB, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000; 60:1968-1973.
34. Franke W, Neumann NJ, Ruzicka T, Schulte KW. Plantar malignant melanoma - a challenge for early recognition. Melanoma Res 2000; 10:571-576.
35. Watabe H, Valencia JC, Yasumoto K, Kushimoto T, Ando H, Muller J, et al. Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity. J Biol Chem 2004; 279:7971-7981.
36. Halaban R, Cheng E, Zhang Y, Moellmann G, Hanlon D, Michalak M, et al. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci USA 1997; 94:6210-6215.
37. Orlow SJ, Hearing VJ, Sakai C, Urabe K, Zhou BK, Silvers WK, et al. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc Natl Acad Sci USA 1995; 92:10152-10156.
38. Orlow SJ, Silvers WK, Zhou BK, Mintz B. Comparative decreases in tyrosinase, TRP-1, TRP-2, and Pmel17/silver antigenic proteins from melanotic to amelanotic stages of syngeneic mouse cutaneous melanomas and metastases. Cancer Res 1998; 58:1521-1523.
39. Choi C, Kusewitt DF. Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas. Vet Pathol 2003; 40:713-718.
40. Smedley RC, Lamoureux J, Sledge DG, Kiupel M. Immunohistochemical diagnosis of canine oral amelanotic melanocytic neoplasms. Vet Pathol 2011; 48:32-34.
41. Cheung WL, Patel RR, Leonard A, Firoz B, Meehan SA. Amelanotic melanoma: a detailed morphologic analysis with clinicopathologic correlation of 75 cases. J Cutan Pathol 2012; 39:33-39.
42. Elder DE, Elenitsas R, Murphy GF, Xu X. Benign pigmented lesions and malignant melanoma. In: Elder DE, Elenitsas R, Johnson BL, Murphy GF, editors. Lever's histopathology of the skin. 9th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2005. pp. 728-730.
43. Florell SR, Bowen AR, Hanks AN, Murphy KJ, Grossman D. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol 2005; 32: 45-49.
44. Morales-Ducret CR, van de Rijn M, Smoller BR. Bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation. Arch Dermatol 1995; 131:915-918.
45. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
46. Balch CM,Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, MaddoxWA. The prognostic significance of ulceration of cutaneous melanoma as a group, ulcerated lesions are thicker and more likely to have a nodular growth pattern. Cancer 1980; 45:3012-3017.
47. Whiterman DC. Prognostic sub-classification of T1 cutaneous melanomas based on ulceration, tumor thickness and Clark level of invasion. Results of a population-based study from the Swedish Melanoma Register. Br J Dermatol 2013; 168:685-686.
48. Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Res 2007; 9:R89.
49. Kuwai T, Kitadai Y, Tanaka S, Hiyama T, Tanimoto K, Chayama K. Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)- 1alpha. Cancer Sci 2004; 95:149-153.
50. Trimmer C, Whitaker-Menezes D, Bonuccelli G, Milliman JN, Daumer KM, Aplin AE, et al. CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. Cancer Res 2010; 70:7489-7499.
51. Ramirez JA, Guitart J, Rao MS, Diaz LK. Cyclin D1 expression in melanocytic lesions of the skin. Ann Diagn Pathol 2005; 9:185-188.
52. Takata M, Murata H, Saida T. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res 2010; 23:64-71.
53. Alao JP, Gamble SC, Stavropoulou AV, Pomeranz KM, Lam EW, Coombes RC, et al. The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer 2006; 5:7.
54. Sumrejkanchanakij P, Tamamori-Adachi M, Matsunaga Y, Eto K, Ikeda MA. Role of cyclin D1 cytoplasmic sequestration in the survival of postmitotic neurons. Oncogene 2003; 2:8723-8730.
55. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000; 60:481-489.
56. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, et al. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 2005; 65:692-697.
57. Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumorspecific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res 2009; 69:2817-2825.
58. Trisciuoglio D, Desideri M, Ciuffreda L, Mottolese M, Ribatti D, Vacca A, et al. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 2005; 205:414-421.
59. Kumar P, Ning Y, Polverini PJ. Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab Invest 2008; 88:740-749.